StockData
Cigna Group logo

Cigna Group

CINYSEHospital & Medical Service PlansFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026Score 8/30
$295.19−3.04 (-1.02%)

Close on Nov 2, 2026Market cap $78.00BP/E –Yield 2.05%

Cigna Pharmaceutical Manufacturer Receivables by Year

Pharmaceutical Manufacturer Receivables — Drug Rebates & Discounts Receivable ($M) ($M)

Cigna Pharmaceutical Manufacturer Receivables: $12,437M in FY2025.

Latest, FY2025
12,437
Period ended Dec 31, 2025
Change on a year earlier
–
History
5 years
Since FY2018
Sources
5
Documents cited below

Where the FY2025 figure comes from

Source: SEC Form 10-Q (filed 2026-07-30) ↗

Rebates & administrative fees due from pharmaceutical manufacturers (hidden inside consolidated Accounts Receivable on the GAAP balance sheet).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPharmaceutical Manufacturer Receivables — Drug Rebates & Discounts Receivable ($M) ($M)Year on yearSource
FY2025Dec 31, 202512,437–SEC Form 10-Q (filed 2026-07-30) ↗
FY2022Dec 31, 20227,108–SEC Form 10-K (filed 2024-02-29) ↗
FY2020Dec 31, 20204,676+36.0%SEC Form 10-K (filed 2022-02-24) ↗
FY2019Dec 31, 20193,439+3.6%SEC Form 10-K (filed 2021-02-25) ↗
FY2018Dec 31, 20183,321–SEC Form 10-K (filed 2020-02-27) ↗

Cite this data

StockData. (2026). Cigna Pharmaceutical Manufacturer Receivables ($M), annual FY2018–FY2025 [Data set]. Compiled from Cigna SEC filings and investor materials. https://stockdatahq.com/stocks/ci/kpis/pharma-mfg-receivable

See every metric in the Cigna KPI table. Data updated Oct 31, 2026.